Scarica l'app Stockscreener
5.82
0.34%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.84
Aprire:
$5.89
Volume 24 ore:
2.09M
Relative Volume:
1.09
Capitalizzazione di mercato:
$438.36M
Reddito:
$13.38M
Utile/perdita netta:
$-241.11M
Rapporto P/E:
-1.3667
EPS:
-4.2584
Flusso di cassa netto:
$-140.93M
1 W Prestazione:
-12.74%
1M Prestazione:
-19.17%
6M Prestazione:
-27.43%
1 anno Prestazione:
-4.75%
Intervallo 1D:
$5.795
$6.20
Intervallo di 1 settimana:
$5.795
$6.805
Portata 52W:
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.82 | 439.87M | 13.38M | -241.11M | -140.93M | -4.2584 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-04 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Iniziato | Jefferies | Buy |
| 2025-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Gap Down: What analysts say about Verastem Inc stock2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
VSTM: Strong sales, robust clinical progress, and major data updates expected mid-year - TradingView
FY2025 EPS Estimates for Verastem Increased by HC Wainwright - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Verastem, Inc. (VSTM) Stock Analysis: Exploring the 164.73% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
HC Wainwright Forecasts Verastem FY2025 Earnings - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Minerva Neurosciences (NERV) and Verastem (VSTM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail
Verastem Extends Cash Runway and Highlights 2025 Results - The Globe and Mail
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results - The Globe and Mail
Verastem Inc (VSTM) CEO Dan Paterson Sells 970 Shares - GuruFocus
HC Wainwright Estimates Verastem FY2030 Earnings - MarketBeat
VSTM: HC Wainwright & Co. Assumes 'Buy' Rating with Price Target of $18.00 | VSTM Stock News - GuruFocus
Verastem Oncology: Preliminary Q4/2025 Revenue and Business Updates; 2026 Priorities for Novel RAS/MAPK Pathway-Driven Cancer Portfolio - marketscreener.com
Verastem Projects $17.5 Million Net Revenue for Q4 2025 - Intellectia AI
Verastem (VSTM) Makes Strides with Innovative Cancer Treatments - GuruFocus
Verastem (NASDAQ:VSTM) Now Covered by HC Wainwright - MarketBeat
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target - Investing.com Nigeria
Verastem stock rating initiated at Buy by H.C. Wainwright with $18 target - Investing.com Canada
B.Riley reiterates Buy rating on Verastem stock, maintains $16 target By Investing.com - Investing.com South Africa
Verastem reports $17.5 million in Q4 revenue for cancer treatment By Investing.com - Investing.com Canada
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
RBC Capital Remains a Buy on Verastem (VSTM) - The Globe and Mail
Verastem, Inc. (VSTM): Investor Outlook With A Potential Upside Of 151.56% - DirectorsTalk Interviews
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - Cantech Letter
ETF Watch: Is Verastem Inc forming a double bottomWeekly Gains Report & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Breakout Zone: What is the Moat Score of Verastem IncJuly 2025 Market Mood & Safe Capital Growth Tips - baoquankhu1.vn
Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up - TipRanks
Retail Trends: Does Verastem Inc have a competitive edgeJuly 2025 Levels & Risk Controlled Swing Alerts - baoquankhu1.vn
Have Verastem Insiders Been Selling Stock? - simplywall.st
CEO Change: Is Icahn Enterprises LP showing insider buyingJuly 2025 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Resistance Check: Does Verastem Inc outperform in volatile markets2025 Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Insider Sell: Dan Paterson Sells Shares of Verastem Inc (VSTM) - GuruFocus
Daniel Calkins Sells 5,039 Shares of Verastem (NASDAQ:VSTM) Stock - MarketBeat
Insider Selling: Verastem (NASDAQ:VSTM) CEO Sells 10,321 Shares of Stock - MarketBeat
EPS Watch: Why Verastem Inc stock is trending among retail tradersTrade Risk Assessment & Reliable Entry Point Alerts - Bộ Nội Vụ
Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM) - The Globe and Mail
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Chartmill
Polar Capital Holdings Plc Increases Stake in Verastem Inc - GuruFocus
Verastem, Inc. (VSTM) Investor Outlook: Biotech Stock With Over 100% Potential Upside - DirectorsTalk Interviews
Can Verastem Inc. stock continue upward trendJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
Is Verastem Inc. stock attractive after correctionMarket Performance Recap & Verified Short-Term Trading Plans - ulpravda.ru
Will Verastem Inc. stock attract more institutional investorsJuly 2025 Outlook & Safe Entry Point Identification - Улправда
Verastem updates oncology strategy in new corporate presentation - TipRanks
RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer - Seeking Alpha
Verastem (NASDAQ:VSTM) Shares Up 19.3%Should You Buy? - MarketBeat
Verastem shifts focus to KRAS G12D and pancreatic programs - MSN
Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects - MSN
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):